Physician profile
Nadia Yimer
NPI 1073000618
$10,810.86
in general payments reported to CMS, 2019-2025
19 companies · $4,883 in 2025
The $4,883 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $5,928 · 2025: $4,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,500 · Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,500.00 |
| Food and Beverage | $2,310.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,541.76 | 2024-2025 | |
| Genzyme Corporation | $503.93 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $251.29 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $198.66 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $185.84 | 2025 | Prolastin-C Liquid |
| Baxter Healthcare | $184.20 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Glaxosmithkline, LLC. | $151.91 | 2024-2025 | Nucala, Trelegy Ellipta |
| Mallinckrodt Hospital Products INC. | $118.67 | 2025 | Acthar |
| Viatris Specialty LLC | $104.84 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.47 | 2025 | Ofev, Jascayd |
| Amgen INC. | $80.05 | 2024-2025 | Tezspire |
| Verona Pharma, INC. | $74.95 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $70.32 | 2024-2025 | Opsumit, Uptravi |
| Insmed, INC. | $67.04 | 2024-2025 | Arikayce |
| Lilly USA, LLC | $49.57 | 2025 | Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $43.77 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $36.93 | 2024-2025 | Glassia |
| Axsome Therapeutics, INC. | $34.06 | 2025 | Sunosi |
| Inspire Medical Systems, INC. | $20.60 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Yimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.